TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Skye Bioscience, Inc. (NASDAQ: SKYE) Securities Class Action: Johnson Fistel Reminds Investors of January 16 Deadline to Seek Lead Plaintiff Appointment

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Johnson Fistel, Pllp
Skye Bioscience, Inc. (NASDAQ: SKYE) Securities Class Action: Johnson Fistel Reminds Investors of January 16 Deadline to Seek Lead Plaintiff Appointment

Johnson Fistel announces a class action lawsuit against Skye Bioscience for investors who purchased securities between November 4, 2024 and October 3, 2025. The lawsuit alleges the company made materially false and misleading statements about its drug candidate nimacimab, overstating its effectiveness and commercial prospects. Investors must seek lead plaintiff appointment by January 16, 2026.

Insights
SKYE   negative

The company is the subject of a securities class action lawsuit alleging material misrepresentations about its drug candidate's effectiveness and commercial prospects, resulting in substantial investor losses when the truth was disclosed on October 3, 2025.